...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Postoperative radiation for prevention of heterotopic ossification of the elbow: primary or secondary prophylaxis? In regard to Robinson CG et al. (Int J Radiat Oncol Biol Phys 2010;77:1493-1499).
【24h】

Postoperative radiation for prevention of heterotopic ossification of the elbow: primary or secondary prophylaxis? In regard to Robinson CG et al. (Int J Radiat Oncol Biol Phys 2010;77:1493-1499).

机译:术后放射线预防肘部异位骨化:主要还是次要预防措施?关于罗宾逊CG等。 (Int J Radiat Oncol Biol Phys 2010; 77:1493-1499)。

获取原文
获取原文并翻译 | 示例
           

摘要

We read the paper wrote by Dr. Kidd et al. with high interest (1). It was the first clinical report about the intensity-modulated radiotherapy (IMRT) technique used for treating a large scale of patients with cervical cancer for curative intent. It also had a 3-year follow-up and non-IMRT control result. However, there is a lack of clarity in three items. 1. It seems that the differences of overall survival and cause-specific survival in two groups are not related with the radiation technique, because the difference of pelvic recurrence is not significant (18/135 [13.3%] vs. 61/317 [19.2%], p > 0.05] and the tumor volume in two of the groups is not clear.2. Although the Grade 3 or greater complications are lower in the IMRT group (4%) than in no-IMRT group (17%), the Radiation Therapy Oncology Group Grade 2 complications also obviously affect the life quality of patients. 3. How about the relationship between the dose at organs at risk reference point and the complication? Is there a threshold for harmless dose to organs at risk in present study as in many other studies (2)?
机译:我们阅读了Kidd博士等人撰写的论文。兴趣很高(1)。这是关于强度调制放射疗法(IMRT)技术用于治疗大规模宫颈癌患者的第一个临床报告,旨在达到治愈目的。它还有3年的随访和非IMRT控制结果。但是,三项内容不够明确。 1.两组的总生存率和特定原因生存率的差异似乎与放射线技术无关,因为盆腔复发的差异并不显着(18/135 [13.3%]与61/317 [19.2] %],p> 0.05],两组中的肿瘤体积均不清楚。2。尽管IMRT组(4%)的3级或更高并发症发生率低于非IMRT组(17%),放射治疗肿瘤学组2级并发症也明显影响患者的生活质量3.危险参考点处器官的剂量与并发症之间的关系如何?本研究中是否存在对危险器官无害剂量的阈值像其他许多研究一样(2)?

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号